Study for Patients with Hepatocellular Carcinoma (HCC)

Clinical Trial Title

Phase III, multicenter, randomized, open label study of atezolizumab (anti Pd-L1 antibody) plus bevacizumab versus active surveillance as adjuvant therapy in patients with hepatocellular carcinoma.

National Clinical Trial Number:

NCT04102098

Contact Information

Rush Cancer Center Clinical Trials Office

Clinical Trial Protocol Description:

The purpose of this study is to compare the effects, good or bad, of atezolizumab plus bevacizumab versus observation (not receiving any treatment) on patients with completely resected or ablated HCC who are at high risk for disease recurrence. In this study, you will get either atezolizumab plus bevacizumab or no treatment.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Are at least 18 years old.
  • Have a first diagnosis of HCC and have undergone a curative resection or ablation (RFA or MWA only).
  • Are fully recovered from surgical resection or ablation within four weeks prior to randomization.

This is a partial list of elgibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.

Study Details

Clinical Trial Investigator

Ashiq Masood, MD

Contact Information

Rush Cancer Center Clinical Trials Office

Location

Rush University Medical Center

1620 W Harrison St
Chicago, IL 60612

Get Directions

Clinical Trial FAQs

Find out if a clinical trial makes sense for you.

Learn more
Learn more